close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Alnylam Pharmaceuticals, Inc. - Common Stock (NQ:ALNY)

436.38 -9.41 (-2.11%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 21, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Alnylam Pharmaceuticals, Inc. - Common Stock

< Previous 1 2
...
14 15 16 17 18 19 20 21 Next >
News headline image
Alnylam Reports Positive Topline Results from Phase 2 Study of Investigational Cemdisiran for the Treatment of IgA Nephropathy
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For June 7, 2022 ↗
Upgrades 
Via Benzinga
News headline image
Analyst Ratings for Alnylam Pharmaceuticals ↗
Analysts have provided the following ratings for Alnylam Pharmaceuticals (NASDAQ:ALNY) within the last quarter: 
Via Benzinga
News headline image
Alnylam's Lumasiran Shows Clinical Benefit In Rare Kidney Disease ↗
 
Via Benzinga
News headline image
Why HC Wainwright Is Bullish On This Stock's Hepatitis-B Pipeline ↗
 
Via Benzinga
News headline image
Alnylam to Webcast Presentations at Upcoming June Investor Conferences
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Alnylam Announces Publication of Preclinical Results Based on Novel Conjugate Technology That Facilitates Delivery of Short Interfering RNA to the Central Nervous System and Other Extrahepatic Tissues
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Alnylam Presents New Results from the ILLUMINATE-C Phase 3 Study of Lumasiran in Patients with Advanced Primary Hyperoxaluria Type 1
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Analyst Ratings for Alnylam Pharmaceuticals ↗
Alnylam Pharmaceuticals (NASDAQ:ALNY) has observed the following analyst ratings within the last quarter: 
Via Benzinga
News headline image
Alnylam Presents New 18-Month Results from Exploratory Cardiac Endpoints in HELIOS-A Phase 3 Study of Investigational Vutrisiran
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Alnylam to Webcast Presentations at Upcoming May Investor Conferences
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
10 Biggest Price Target Changes For Monday ↗
Morgan Stanley boosted Archer-Daniels-Midland Company (NYSE: ADM) price target from $69 to $94. Archer-Daniels-Midland shares fell 0.5% to $89.10 in pre-market trading. 
Via Benzinga
News headline image
See Why Did FDA Extend Review Period For Alnylam's Vutrisiran In Amyloidosis ↗
 
Via Benzinga
News headline image
Expert Ratings for Alnylam Pharmaceuticals ↗
Over the past 3 months, 10 analysts have published their opinion on Alnylam Pharmaceuticals (NASDAQ:ALNY) stock. These analysts are typically employed by large Wall Street banks and tasked with... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Moderna Seeks FDA Approval For COVID-19 Shot For Children 2-6, Tax Disclosure For Amgen, Fast Track Tags For SQZ Biotech, Timber Pharma Candidates ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
Alnylam Pharmaceuticals Reports First Quarter 2022 Financial Results and Highlights Recent Period Activity
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
What To Know About Morgan Stanley's Downgrade of Alnylam Pharmaceuticals ↗
Morgan Stanley downgraded its rating of Alnylam Pharmaceuticals (NASDAQ:ALNY) to Equal-Weight with a price target of $178.00, changing its price target from $210.00 to $178.00. Shares of Alnylam... 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For April 25, 2022 ↗
 
Via Benzinga
News headline image
The Week Ahead In Biotech (April 24-April 30): Bristol-Myers Squibb, Supernus, Hutchmed, Axsome, Coherus FDA Decisions, Big Pharma Earnings, IPOs And More ↗
Biotech stocks extended their loses in the week ending April 22. The sector took cues from the broader market, which reacted to the lackluster start of the first-quarter reporting season and lingering... 
Via Benzinga
News headline image
7 Potential Biotech Stocks Buyout Targets in 2022 ↗
Drug development is a cumbersome process and M&A is a win-win proposition for both the acquirer and the target company. 
Via InvestorPlace
News headline image
Alnylam Pharmaceuticals Q1 2022 Earnings Conference Call On April 28, 2022 At 08:30 AM ET ↗
Alnylam Pharmaceuticals (NASDAQ:ALNY) will host a conference call at 08:30 AM ET on April 28, 2022, to discuss Q1 2022 earnings results. 
Via Benzinga
News headline image
Alnylam to Webcast Conference Call Discussing First Quarter 2022 Financial Results
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Alnylam Announces Retirement of Steven Paul, M.D. from Board of Directors
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Alnylam Announces 3-Month Extension of Review Period for New Drug Application for Vutrisiran
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Attention Biotech Investors: Mark Your Calendar For April PDUFA Dates ↗
Biopharma stocks are sensitive to a key binary event called the PDUFA date, the date by which the Food and Drug Administration is required to give its verdict on a regulatory application filed with... 
Via Benzinga
News headline image
Alnylam to Webcast Presentation at Stifel 2022 CNS Days
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
World Markets News For Friday ↗
Buoyant global markets are closing the week and one good performer, Vir Biotech, today gained an impressive 6.09%. 
Via Talk Markets
News headline image
Maker Of Pfizer's COVID-19 Vaccine mRNA-Delivery Tech Sues Arbutus Biopharma: Reuters ↗
Canada-based Acuitas Therapeutics Inc has sued Arbutus Biopharma Corporation (NASDAQ: ABUS) in Manhattan federal court, seeking to head off claims that the vaccine infringes Arbutus' patents,  
Via Benzinga
News headline image
Alnylam Hits Pfizer, Moderna With Patent Infringement Suits ↗
 
Via Benzinga
News headline image
Alnylam Pharmaceuticals Files Patent Infringement Suits against Pfizer and Moderna
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
< Previous 1 2
...
14 15 16 17 18 19 20 21 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today